Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN loss |
| Therapy | Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin |
| Indication/Tumor Type | stomach cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN loss | stomach cancer | sensitive | Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin | Preclinical - Pdx | Actionable | In a preclinical study, the combination of Ipatasertib (GDC-0068) and FOLFOX inhibited tumor growth in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-negative gastric cancer harboring PTEN loss, and demonstrated increased activity over either agent alone (PMID: 32205017). | 32205017 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32205017) | Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. | Full reference... |